Drug Search Results
More Filters [+]

Fumagillin

Alternative Names: fumagillin, gw-642444, gw642444, gw 642444
Latest Update: 2024-04-04
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: Angiogenesis Inhibitor,METAP2 Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Inhalant

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: France

Approved Indications: None

Known Adverse Events: None

Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Fumagillin

Countries in Clinic:

Active Clinical Trial Count: 1

Highest Development Phases

Phase 3: Asthma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2017-001532-19

P3

Active, not recruiting

Asthma

2021-03-11

Recent News Events